Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 28, 2005Journal of Clinical Oncology

Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

Thomas E. WitzigThomas E. WitzigUniversité Claude Bernard Lyon 1SGSusan M. GeyerToyota Motor Corporation (Switzerland)IGIrene M. GhobrialBroad Institute

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Witzig et al. (2005) studied this question.

synapsesocial.com/papers/6a158eb6a2352da347829d09https://doi.org/10.1200/jco.2005.13.466
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phosphorylation of the Translational Repressor PHAS-I by the Mammalian Target of Rapamycin1997 · 977 citations
  2. 2High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission.1998 · 186 citations
  3. 3Upstream and downstream of mTOR2004 · 4,244 citations
  4. 4Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma2004 · 528 citations